This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
HealthdirectFree Australian health advice you can count on.
INN: ruxolitinib
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇵🇹🇸🇰🇹🇷
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Novartis Europharm Limited
ATC Code
L01EJ01
Source
EMA · EMEA/H/C/002464
(
ARTG
)
Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,Jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.
⚠️ Warnings
• Caution should be exercised in patients with history of liver or kidney impairment, patients on dialysis, during pregnancy and breastfeeding.
• It may cause dizziness, avoid performing any hazardous activity while taking this medication.
• Patient may develop with certain types of infection; discuss with your healthcare provider before taking this medication.
• It may reduce platelet counts; avoid injury or bruising.
• Monitor complete blood count regularly while taking this medication.
